Journal Article

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

Gilbert, Lucy, Tinker, Anna V, Mathews, Cara, O’Malley, David M, Boni, Valentina, Zildjian, Sybil, Oaknin, Ana, Han, Xinwei, Press, Joshua, Veneris, Jennifer, Ghamande, Sharad, Brown, Jubilee, Duska, Linda, Pothuri, Bhavana, Guo, Wei, Duan, Tao, Leath III, Charles, Kristeleit, Rebecca, Ghatage, Prafull, Im, Ellie, Samouelian, Vanessa, Sabatier, Renaud

2022

Overview

BackgroundDostarlimab is a humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. We report interim data from patients with endometrial cancer (EC) participating in a phase I trial of single-agent dostarlimab.MethodsGARNET, an ongoing, single-arm, open-label, phase I trial of intravenous dostarlimab in advanced solid tumors, is being undertaken at 123 sites. Two cohorts of patients with EC were recruited: those with dMMR/MSI-H disease (cohort A1) and those with proficient/stable (MMRp/MSS) disease (cohort A2). Patients received dostarlimab 500 mg every 3 weeks for 4 cycles, then dostarlimab 1000 mg every 6 weeks until disease progression. The primary endpoints were objective response rate (ORR) and duration of response (DOR) per RECIST V.1.1, as assessed by blinded independent central review.ResultsScreening began on April 10, 2017, and 129 and 161 patients with advanced EC were enrolled in cohorts A1 and A2, respectively. The median follow-up duration was 16.3 months (IQR 9.5–22.1) for cohort A1 and 11.5 months (IQR 11.0–25.1) for cohort A2. In cohort A1, ORR was 43.5% (95% CI 34.0% to 53.4%) with 11 complete responses and 36 partial responses. In cohort A2, ORR was 14.1% (95% CI 9.1% to 20.6%) with three complete responses and 19 partial responses. Median DOR was not reached in either cohort. In the combined cohorts, the majority of treatment-related adverse events (TRAEs) were grade 1–2 (75.5%), most commonly fatigue (17.6%), diarrhea (13.8%), and nausea (13.8%). Grade≥3 TRAEs occurred in 16.6% of patients, and 5.5% discontinued dostarlimab because of TRAEs. No deaths were attributable to dostarlimab.ConclusionDostarlimab demonstrated durable antitumor activity in both dMMR/MSI-H (ORR 43.5%) and MMRp/MSS EC (ORR 14.1%) with a manageable safety profile.Trial registration numberNCT02715284.

• Publisher: BMJ Publishing Group Ltd,BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Antibodies, Monoclonal, Humanized - pharmacology / Antibodies, Monoclonal, Humanized - therapeutic use / Biomarkers / Biomarkers, Tumor - metabolism / Cancer / Cell death / clinical trials as topic / Clinical/Translational Cancer Immunotherapy / DNA Mismatch Repair - drug effects / Endometrial cancer / Endometrial Neoplasms - drug therapy / Enrollments / Female / Humans / Hypotheses / Immunotherapy / Laboratories / Life Sciences / Microsatellite Instability - drug effects / Middle Aged / Monoclonal antibodies / Mutation / Patients / programmed cell death 1 receptor / Proteins / Response rates / Targeted cancer therapy / Tumors